Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea

NCT01426269 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT01426269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea
Lead sponsor
Galderma R&D
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2011
Completion date
June 30, 2013
Enrollment
235 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea